title: Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study.
abstract: We report the results of a prospective randomised study to evaluate the therapeutic effect of Serenoa repens, Urtica dioica (ProstaMEV), quercitin and curcumin (FlogMEV) extracts associated with prulifloxacin in patients affected by chronic bacterial prostatitis (CBP). From a whole population of 284 patients, 143 patients affected by CBP [National Institutes of Health (NIH) class II prostatitis] were enrolled. All patients received prulifloxacin 600 mg daily for 14 days, in accordance with antibiogram results. Patients were split into two groups: Group A received prulifloxacin associated with ProstaMEV and FlogMEV; Group B received only antibiotic therapy. Microbiological and clinical efficacies were tested by two follow-up visits at 1 month and 6 months, respectively. Quality of life (QoL) was measured using the NIH Chronic Prostatitis Symptom Index (CPSI) and International Prostatic Symptom Score (IPSS) questionnaires. Group A comprised 106 patients and Group B comprised 37 patients. One month after treatment, 89.6% of patients who had received prulifloxacin associated with ProstaMEV and FlogMEV did not report any symptoms related to CBP, whilst only 27% of patients who received antibiotic therapy alone were recurrence-free (P < 0.0001). Significant differences were found between groups in terms of symptoms and QoL (P < 0.0001 for both). Six months after treatment, no patients in Group A had recurrence of disease whilst two patients in Group B did. Questionnaire results demonstrated statistically significant differences between groups (all P < 0.001). The association of S. repens, U. dioica (ProstaMEV), quercitin and curcumin (FlogMEV) extracts is able to improve the clinical efficacy of prulifloxacin in patients affected by CBP.
authors.affiliation: Department of Urology, University of Florence, via dell'Antella 58, 50011 Florence, Italy. ktommy@libero.it
authors.forename: Tommaso
authors.initials: T
authors.lastname: Cai
authors.forename: Sandra
authors.initials: S
authors.lastname: Mazzoli
authors.forename: Adriano
authors.initials: A
authors.lastname: Bechi
authors.forename: Patrizia
authors.initials: P
authors.lastname: Addonisio
authors.forename: Nicola
authors.initials: N
authors.lastname: Mondaini
authors.forename: Roberto Castricchi
authors.initials: RC
authors.lastname: Pagliai
authors.forename: Riccardo
authors.initials: R
authors.lastname: Bartoletti
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003474:Curcumin / Q000302:isolation & purification / Q000627:therapeutic use*; D004148:Dioxolanes / Q000627:therapeutic use*; D005419:Flavonoids / Q000627:therapeutic use*; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011472:Prostatitis / Q000188:drug therapy*; D011788:Quality of Life / Q000523:psychology; D055502:Secondary Prevention; D028024:Serenoa / Q000737:chemistry*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D026982:Urtica dioica / Q000737:chemistry*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D005419:Flavonoids; D024841:Fluoroquinolones; D010879:Piperazines; D003474:Curcumin; C074191:prulifloxacin